Notice2025-19379
Government Owned Inventions Available for Licensing and/or Collaboration: Automated Cell Radiolabeling Device Using Acoustophoresis Micro-Fluidic Technology
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
October 2, 2025
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Cancer Institute (NCI), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), seeks research co-development partners and/or licensees for an automated acoustophoresis device to radio-label and isolate cells. This invention is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development.
Full Text
<html>
<head>
<title>Federal Register, Volume 90 Issue 189 (Thursday, October 2, 2025)</title>
</head>
<body><pre>
[Federal Register Volume 90, Number 189 (Thursday, October 2, 2025)]
[Notices]
[Pages 47783-47784]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2025-19379]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government Owned Inventions Available for Licensing and/or
Collaboration: Automated Cell Radiolabeling Device Using
Acoustophoresis Micro-Fluidic Technology
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Cancer Institute (NCI), an institute of the
National Institutes of Health (NIH), Department of Health and Human
Services (HHS), seeks research co-development partners and/or licensees
for an automated acoustophoresis device to radio-label and isolate
cells. This invention is owned by an agency of the U.S. Government and
is available for licensing to achieve expeditious commercialization of
results of federally-funded research and development.
FOR FURTHER INFORMATION CONTACT: Inquiries related to these licensing
opportunities should be directed to Eric Cheng, Ph.D., Technology
Transfer Manager, NCI, Technology Transfer Center, Email:
<a href="/cdn-cgi/l/email-protection#2643544f4508454e4348411466484f4e08414950"><span class="__cf_email__" data-cfemail="e481968d87ca878c818a83d6a48a8d8cca838b92">[email protected]</span></a> or Phone: 240-276-5978.
SUPPLEMENTARY INFORMATION: This technology includes an automated cell
radiolabeling device that utilizes acoustophoresis microfluidic
technology. The device streamlines the radiolabeling process by
integrating cell washing and concentrating steps, which enhances
reproducibility and standardization. This innovation simplifies the GMP
(Good Manufacturing Practice) compliance for radiolabeling cells
intended for human use. It also addresses the limitations of current
manual methods that rely on centrifugation. The result is a benchtop
system designed for clinical radio-pharmacies, ensuring efficient and
reliable cell preparation for diagnostic and therapeutic applications.
This Notice is in accordance with 35 U.S.C. 209 and 37 CFR part
404.
NIH Reference Number: E-096-2021.
Product Type: Device.
Therapeutic Area(s): Oncology.
View Technology Webinar: Automated Acoustophoresis Device to Radio-
Label & Isolate Cells for Immunotherapy and Isolated Cells for
Immunotherapy Treatment.
Potential Commercial Applications:
<bullet> Clinical radio-pharmacies for radiolabeled cell
diagnostics.
<bullet> Research institutions focused on cellular therapies and
diagnostics.
<bullet> Pharmaceutical companies developing radiolabeled
therapeutics.
Competitive Advantages:
<bullet> Fully automated process reduces manual intervention,
increasing efficiency and consistency.
<bullet> Micron-scale acoustophoresis technology enhances
reproducibility and standardization of cell radiolabeling.
<bullet> Streamlined GMP compliance simplifies regulatory processes
for clinical applications.
<bullet> Benchtop system.
Publication:
<bullet> Adler, S, et al. Using Acoustophoresis Cell Washing In The
Immune Cell Radiolabeling Procedure. (<a href="https://jnm.snmjournals.org/content/63/supplement_2/2755">https://jnm.snmjournals.org/content/63/supplement_2/2755</a>).
Patent Status: U.S. Patent Application 18/290,4425 filed on
November 13, 2023, pending.
Development Stage: Prototype.
Collaboration Opportunity: Researchers at the NCI seek licensing
[[Page 47784]]
and/or co-development research collaborations for an automated
acoustophoresis device to radio-label and isolate cells.
Dated: September 30, 2025.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center. National Cancer
Institute.
[FR Doc. 2025-19379 Filed 10-1-25; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on October 2, 2025.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.